

NAVIGATING THE REAL-WORLD USE OF PARP INHIBITORS IN BRCAm mCRPC: A PRACTICAL DISCUSSION

Monday 12th September 2022, 18:30 – 20:00 CEST
7.3.T – Toulouse Auditorium, Hall 7, Level 7.3,
Paris Expo Porte de Versailles, Paris, France

CHAIR AND SPEAKER



Neal Shore, MD, FACS
Carolina Urologic Research Center, Myrtle Beach, SC, USA

SPEAKERS



Niven Mehra, MD, PhD
Radboud University Medical Center, Nijmegen, The Netherlands



Andrew Armstrong, MD, ScM, FACP
Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA

AGENDA

Welcome and introduction	Neal Shore
Why are PARP inhibitors relevant in the treatment of prostate cancer?	Neal Shore
What data support the clinical activity of PARP inhibitors in mCRPC?	Niven Mehra
Case-based discussion 1: Personalising patient care in BRCAm prostate cancer	Neal Shore Panel discussion
Case-based discussion 2: Practical considerations for the real-world use of PARP inhibitors in mCRPC	Neal Shore Panel discussion
Evolving landscape of PARP inhibitors in mCRPC	Andrew Armstrong
Live Q&A	Neal Shore Niven Mehra Andrew Armstrong

JOIN THE DISCUSSION ON MONDAY 12th SEPTEMBER 2022 • 18:30 – 20:00 CEST

This industry session is organised and sponsored by AstraZeneca; it is a non-promotional, medical-led, peer-to-peer scientific meeting to allow healthcare professionals to share scientific information on the current evidence for the use of PARP inhibitors in prostate cancer and discuss considerations for clinical practice.

This industry session may contain information about investigational products and investigational uses which are not yet approved in the EU.